PSA testing is an important, lifesaving tool to detect prostate cancer in an early stage when it is curable. An abnormal PSA test result may suggest the presence of prostate cancer, but what constitutes an “abnormal” test result? Can the same PSA value be abnormal in one patient but not in another, and how can clinicians provide the best follow-up care in each of these cases?

Hearing from our guest speakers, this webinar will discuss the nuances of PSA test result interpretation, best practices for referring patients to urology, and the role of follow-up tests like MRI and biomarker testing in optimizing prostate biopsy referrals.

Yaw Nyame, MD, MS, MBA– Assistant Professor, Fred Hutchinson Cancer Center, University of Washington

Andrew M.D. Wolf, MD– Professor Emeritus of Medicine, University of Virginia School of Medicine

Peter L. Choyke, MD– Radiologist & Chief, Molecular Imaging Branch, National Cancer Institute

Jeffrey Tosoian, MD, MPH– Assistant Professor & Director, Translational Cancer Research Department of Urology, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center